Nicotine replacement treatment, e-cigarettes and an online behavioural intervention to reduce relapse in recent ex-smokers: a multinational four-arm RCT

Hayden J McRobbie,1,2 Anna Phillips-Waller,1* Catherine El Zerbi,3 Ann McNeill,3 Peter Hajek,1 Francesca Pesola,3 James Balmford,4† Stuart G Ferguson,5 Lin Li,6 Sarah Lewis,7 Ryan J Courtney,2 Coral Gartner,8 Linda Bauld9 and Ron Borland6

1Health and Lifestyle Research Unit, Queen Mary University of London, London, UK
2National Drug and Alcohol Research Centre, University of New South Wales, Randwick, NSW, Australia
3Cancer Prevention Group, School of Cancer & Pharmaceutical Sciences, Faculty of Medicine and Life Sciences, King’s College London, London, UK
4Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg im Breisgau, Germany
5College of Health and Medicine, University of Tasmania, Hobart, TAS, Australia
6Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, VIC, Australia
7Clinical Sciences Building, University of Nottingham, Nottingham City Hospital, Nottingham, UK
8School of Public Health, Faculty of Medicine, University of Queensland, St Lucia, QLD, Australia
9Usher Institute, University of Edinburgh, Edinburgh, UK

*Corresponding author a.phillips-waller@qmul.ac.uk
†In memoriam

Declared competing interests of authors: Hayden J McRobbie reports personal fees from Pfizer Inc. (New York, NY, USA) outside the submitted work. Ann McNeill is a National Institute for Health Research Senior Investigator. Peter Hajek reports grants and personal fees from Pfizer Inc. outside the submitted work. Stuart G Ferguson reports personal fees from Pfizer Inc., Johnson & Johnson (Johnson & Johnson, Brunswick, NJ, USA), GlaxoSmithKline plc (GlaxoSmithKline plc, Brentford, UK) and Chrono Therapeutics Inc. (Cambridge, MA, USA) outside the submitted work. At the time of the study, Lin Li and Ron Borland worked for Cancer Council Victoria (Melbourne, VIC, Australia), which owns the intellectual property for the Structured Planning and Prompting Protocol that was adapted in this trial. Ron Borland co-developed the Structured Planning and Prompting Protocol intervention as part of his former employment at Cancer Council Victoria. James Balmford co-developed the Structured Planning and Prompting Protocol intervention with Ron Borland as part of his former employment at Cancer Council Victoria. Sarah Lewis was a Health Services and Delivery Research Researcher-Led Board Member (2014–16). Linda Bauld is a member of Public Health Research Research Funding Board (2015–present).
Scientific summary

Reducing relapse in recent ex-smokers
Health Technology Assessment 2020; Vol. 24: No. 68
DOI: 10.3310/hta24680

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Most efforts to stop smoking that are initially successful end in relapse. Extended stop smoking medication use can help prevent relapse, but uptake and long-term use are low. Fast-acting nicotine replacement products, such as nicotine mouth spray, lozenges and electronic cigarettes, can be used opportunistically in relapse situations, which may be a more promising (and more economical) approach. Regarding behavioural interventions, although most approaches have been found to be ineffective, a recent trial of an online Structured Planning and Prompting Protocol started at the beginning of the quit attempt reduced relapse between 1 and 26 weeks.

Objectives

We planned to determine if the Structured Planning and Prompting Protocol plus interactive texting, or a provision of fast-acting nicotine products to use in emergencies, or the combination of the two approaches, reduced relapse rates at 12 months post quit date compared with usual care. In addition, we aimed to determine the feasibility and acceptability of the interventions and their cost-effectiveness. The trial also included a qualitative and ecological momentary assessment substudy to explore the relapse process and barriers to and facilitators of relapse prevention. Owing to delays in setting up the online intervention as a result of technical and regulatory issues, problems with recruiting from Australian quitlines and English service restructuring affecting recruitment, the trial was curtailed at 6 months’ follow-up with a reduced sample size. Therefore, the revised (prespecified) objective was whether or not the number of interventions received (i.e. none, one or two) affected relapse rates at 6 months post quit date.

Design

A multicentre randomised controlled trial.

Participants and setting

Originally, we planned to recruit 1400 recent ex-smokers, with 700 participants recruited from English stop smoking services and 700 participants from Australian quitlines. However, because of the issues described, only 234 participants were randomised (n = 131 in Australia and n = 103 in England). Initially, participants were to be recruited when they had achieved at least 4 weeks of abstinence, but, later, participants in Australia were recruited from 1 week post quit date via social media and St Vincent’s Hospital Melbourne, Fitzroy, VIC, Australia.

Study arms

There were four study arms.

1. A fast-acting nicotine product of the participant’s choice (e.g. nicotine mouth spray, lozenge or electronic cigarette) to use if they were at risk of relapse, accompanied by static text messages.
2. A Structured Planning and Prompting Protocol, for which participants received access to the online protocol that offers training in strategies to deal with temptations to smoke and provides motivational input. This was combined with intensive interactive text messaging.


4. Static text messages added to usual care, typically comprising access to stop smoking medications used during the quit attempt for up to 3 months.

Participants in all arms who were recruited through English stop smoking services and Australian quitlines also had access to their usual care alongside their allocated intervention.

Procedures

Participants referred to the study were contacted by the study team to confirm eligibility, obtain consent and collect baseline data via online surveys or telephone. Participants were randomised to one of the four study arms following completion of the baseline survey. Participants in the nicotine product arm received their products by post plus a series of static text messages (a maximum of 33 messages sent over 4 months). The Structured Planning and Prompting Protocol arm participants completed an online assessment that generated tailored advice. Participants could complete new assessments for updated advice at any time. In addition, participants received a minimum of 55 interactive text messages over 6 months that were tailored to their assessment responses. The usual-care group received the same static messages as the nicotine product arm. Participants were followed up online or by telephone at 3 and 6 months. Ninety-four participants from the main study were also recruited to take part in a qualitative interview substudy. The interviews took approximately 30 minutes and were conducted by telephone. The interviews were conducted following both the 3- and 6-month follow-ups and included participants who had lapsed, relapsed or remained abstinent from each of the study arms. Data on the feasibility, acceptability, use and perceived impact of study interventions were collected. At around 8–12 weeks post quit date, 79 participants from the main study took part in an ecological momentary assessment substudy, which involved 4 weeks' monitoring of the use and relationship to cravings and slips of the two interventions using a handheld electronic diary.

Measures and outcomes

The original plan was to collect outcome data at 3, 6 and 12 months post quit date, with biochemical validation of self-reported abstinence at 12 months. However, because of the curtailment of the study, outcome data were collected at only 3 and 6 months. All revised outcomes were prespecified in the statistical analysis plan, which was drafted prior to data download and analysis.

Original primary outcome

The original primary outcome was relapse rate in each study arm. Relapse was defined as smoking on at least 7 consecutive days or any smoking in the last month at the 12-month follow-up. Participants lost to follow-up were assumed to have relapsed.

Curtailed primary outcome

The curtailed primary outcome was relapse rate in arms that received no intervention (i.e. usual care), one intervention (i.e. the Structured Planning and Prompting Protocol or a nicotine product) and two interventions (i.e. Structured Planning and Prompting Protocol plus a nicotine product) at 6 months. Relapse was defined as smoking on at least 7 consecutive days or any smoking in the last month at the 6-month follow-up. Participants lost to follow-up were assumed to have relapsed.
Original secondary outcomes
The original secondary outcomes were sustained abstinence using different criteria to the primary outcome (e.g. point prevalence and shorter-term period prevalence outcomes); sustained reduction in cigarette consumption; evaluations of likely mechanisms of effect, focusing on strategies that were encouraged and participant perceptions of effect (e.g. participant ratings and data from the ecological momentary assessment/qualitative substudies); dose–response effects; cost-effectiveness; effects of intervention components by country and by demographic; and adverse events.

Curtailed secondary outcomes
The curtailed secondary outcomes were sustained (i.e. no more than five cigarettes smoked since 2 weeks post quit date) and point prevalence (i.e. no smoking in the past 7 days) abstinence at 3 and 6 months; nicotine product preferences (e.g. electronic cigarette or nicotine replacement treatment); product use at 6 months (i.e. frequency of use of nicotine, number of assessments completed for the Structured Planning and Prompting Protocol, number of text messages read); use of coping strategies (i.e. prespecified list with yes/no answers based on the Structured Planning and Prompting Protocol strategies, plus ecological momentary assessment data); adverse events (free text); participant ratings (e.g. five-point scale from very useful to very useless); and qualitative feedback on the interventions.

Sample size
In our original sample size calculations we expected that 70% of participants would relapse by 12 months in usual care, that each relapse prevention intervention would reduce the rate to 58% and that the combination of the two interventions would result in a 48% relapse rate. Assuming no interaction and comparisons between those who received (two arms) and those who did not receive (two arms) each intervention individually, 257 participants were needed per arm to detect this difference (90% power, alpha = 0.025, two-sided). We aimed to recruit 300 participants in each arm, with an additional 50 participants per arm for the ecological momentary assessment substudy. However, with our reduced sample size of 234 participants, we used an alternative (prespecified) approach that compared the number of interventions (i.e. no intervention (usual care), one intervention (Structured Planning and Prompting Protocol or a nicotine product) or two interventions (Structured Planning and Prompting Protocol plus a nicotine product)) and avoided multiple testing. Using one-tailed alpha = 0.05, the sample size afforded 78% power to detect the differences in relapse rates as estimated above. Ninety-four participants were recruited for the qualitative substudy and 79 participants were recruited for the ecological momentary assessment substudy.

Results
The 6-month relapse rate was 60.0% (95% confidence interval 47% to 71%) in the usual-care arm, 43.5% (95% confidence interval 35% to 53%) in those receiving one intervention [nicotine replacement treatment 44.8% (95% confidence interval 33% to 58%); Structured Planning and Prompting Protocol 42.1% (95% confidence interval 30% to 55%)] and 49.2% (95% confidence interval 37% to 62%) in those receiving two interventions ($p = 0.11$). The secondary outcome of sustained abstinence rate at 6 months was 41.7% in the usual-care arm, 54.8% in the arm receiving one intervention (nicotine replacement treatment 53.5%, Structured Planning and Prompting Protocol 56.1%) and 50.9% in the arm receiving two interventions ($p = 0.17$). In the two study arms that were offered a nicotine product, electronic cigarettes were chosen more frequently than nicotine replacement treatment in Australia (71.0% vs. 29.0%; $p = 0.001$), but not in England (54.0% vs. 46.0%; $p = 0.57$). Most participants tried their products and 23.1% were still using them daily at 6 months (26.8% using electronic cigarettes and 17.1% using nicotine replacement treatment). The Structured Planning and Prompting Protocol received positive ratings (somewhat or very useful) from 63.0% of participants who provided the ratings at 6 months, regardless of whether or not the nicotine product intervention was added to
the Structured Planning and Prompting Protocol. Eighty-six per cent of participants allocated to the Structured Planning and Prompting Protocol completed at least one assessment and > 60% of participants in the Structured Planning and Prompting Protocol arms also reported that they read the online advice, at least briefly. Overall, the site was rarely revisited and coping strategies imparted by the Structured Planning and Prompting Protocol were used with similar frequency in all study arms. Only one participant used the Structured Planning and Prompting Protocol interactive texting feature. Tailored and static text messages received virtually identical ratings. The qualitative study suggested that access to the Structured Planning and Prompting Protocol intervention could be simplified.

Limitations

The inability to recruit sufficient participants resulted in a lack of power to detect clinically relevant differences. Self-reported abstinence was not biochemically validated. The intervention started after a period of abstinence, perhaps reducing the perceived relevance of interventions offered to participants. The study included some smokers who were abstinent for only 7 days during their hospital stay.

Conclusions

Adherence to nicotine products was high, and the online intervention was appreciated but not widely used. There was a trend in favour of single treatments (when compared with usual care), but it did not reach statistical significance and the two interventions combined did not seem to be effective. The study is underpowered and so further evaluation is warranted.

Trial registration

This trial is registered as ISRCTN11111428.

Funding

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 68. See the NIHR Journals Library website for further project information. Funding was also provided by the National Health and Medical Research Council, Canberra, ACT, Australia (NHMRC APP1095880). Public Health England provided the funds to purchase the nicotine products in England.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 13/155/05. The contractual start date was in April 2016. The draft report began editorial review in January 2020 and was accepted for publication in July 2020. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen’s Printer and Controller of HMSO 2020. This work was produced by McRobbie et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Editor-in-Chief of *Health Technology Assessment* and NIHR Journals Library

**Professor Ken Stein**  Professor of Public Health, University of Exeter Medical School, UK

NIHR Journals Library Editors

**Professor John Powell**  Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

**Professor Andrée Le May**  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

**Professor Matthias Beck**  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

**Dr Tessa Crilly**  Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin**  Senior Scientific Advisor, Wessex Institute, UK

**Dr Peter Davidson**  Consultant Advisor, Wessex Institute, University of Southampton, UK

**Ms Tara Lamont**  Senior Scientific Adviser (Evidence Use), Wessex Institute, University of Southampton, UK

**Dr Catriona McDaid**  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

**Professor William McGuire**  Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads**  Emeritus Professor of Wellbeing Research, University of Winchester, UK

**Professor John Norrie**  Chair in Medical Statistics, University of Edinburgh, UK

**Professor James Raftery**  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma**  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts**  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

**Professor Jonathan Ross**  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks**  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Ken Stein**  Professor of Public Health, University of Exeter Medical School, UK

**Professor Jim Thornton**  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

**Professor Martin Underwood**  Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: [www.journalslibrary.nihr.ac.uk/about/editors](http://www.journalslibrary.nihr.ac.uk/about/editors)

**Editorial contact:** journals.library@nihr.ac.uk